

01-13-09

15:21

From-BAKER DONELSON BEARMAN CADWELL BERKOWITZ 202-508-3402

T-717 P.002/003 F-182



Docket No.: I108 1110 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Peter BROSSART et al.

Serial No.: 10/019,513

Filed: August 6, 2002

Confirmation No.: 8680

Art Unit: 1642

Examiner: Suan Nmn Ungar

For: PEPTIDE FOR TRIGGERING AN IMMUNE REACTION AGAINST
TUMOR CELLS

**REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND
CHANGE OF CORRESPONDENCE ADDRESS,
and
STATEMENT UNDER 37 CFR 3.73(b)**

Immatics Biotechnologies GmbH, being the assignee of the entire interest (see below Statement Under 37 CFR 3.73(b)) in the above-identified patent application, (i) hereby revokes all previous powers of attorney given in the above-identified application, and (ii) hereby appoints the practitioners associated with Customer Number 84331 as attorneys/agents to prosecute the application identified above and to transact all business in the United States Patent and Trademark Office connected therewith, this appointment being effective at least as of the date set out below.

Please recognize or change the correspondence address for the above-identified application to the address associated with Customer Number 84331.

STATEMENT UNDER 37 CFR 3.73(b)

Immatics Biotechnologies GmbH, a German corporation, states that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from

RECEIVED
OIPEAP

JAN 28 2009

01-13-09

15:21

From-BAKER DONELSON BEARMAN CADWELL BERKOWITZ 202-508-3402

T-717 P.003/003 F-182


the inventors of the patent application identified above to the current assignee. The assignment was recorded in the United States Patent and Trademark Office at Reel 015285, Frame 0620.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

12/03/2008
Date

By:


Name: Dr. Harpreet Singh
Title: Managing Director CSO

Dr. Niels Emmerich
Managing Director COO